MORPHOLOGICAL AND CHEMICAL PROPERTIES OF SPHERICAL AND NEEDLE CALCIUM PHOSPHATE BIONS

Aim. To compare morphological properties, mineral, and organic profile of spherical calcium phosphate bions (SCPB) and needle calcium phosphate bions (NCPB) for the assessment of the CPB-specific endothelial toxicity in models of mild or severe hypercalcemia/hyperphosphatemia in the further studies.

Methods. Both SCPB and NCPB were artificially synthesized employing blood-mimetic medium either moderately or significantly supersaturated of calcium and phosphorus salts. Size and shape of SCPB and NCPB were investigated by scanning and transmission electron microscopy and atomic force microscopy. Elemental analysis was performed utilizing energy-dispersive X-ray spectroscopy, atomic emission spectroscopy, and CHNSO analysis, functional groups were examined using Fourier-transform infrared spectroscopy and Raman spectroscopy while chemical formula was identified by X-ray powder diffraction analysis. Protein profile of SCPB and NCPB was screened employing sodium dodecyl sulfate polyacrylamide gel electrophoresis following silver staining.

Results. SCPB were visualized as crystalline spherical spongeous particles of 80-200 nm diameter and mean diameter of around 120 nm while NCPB represented needle crystals of a similar diameter. Both SCPB and NCPB had similar crystallinity, surface charge and tended to form clusters of several particles. Furthermore, both SCPB and NCPB were composed of carbon, oxygen, hydrogen, nitrogen, calcium, and phosphorus, contained phosphate (PO4 3-), carbonate (CO3 2-), and hydroxyl (OH- ) functional groups, and consisted of hydroxyapatite (Ca10(PO4 )6 (OH)2 ) and carbonate-hydroxyapatite (Ca10(PO4)3 (CO3)3 (OH)2 ). In addition, protein profile of SCPB and NCPB was similar and notable for the abundant albumin and fetuin A levels.

Conclusion. Having similar size, surface charge, extent of crystallinity, and chemical composition, SCPB and NCPB possess a different shape. 

1. Wu C.Y., Young L., Young D., Martel J., Young J.D. Bions: a family of biomimetic mineralo-organic complexes derived from biological fluids. PLoS One. 2013; 8 (9): e75501. doi: 10.1371/journal.pone.0075501.

2. Kutikhin A.G., Velikanova E.A., Mukhamadiyarov R.A., Glushkova T.V., Borisov V.V., Matveeva V.G., Antonova L.V., Filip'ev D.E., Golovkin A.S., Shishkova D.K., Burago A.Y., Frolov A.V., Dolgov V.Y., Efimova O.S., Popova A.N., Malysheva V.Y., Vladimirov A.A., Sozinov S.A., Ismagilov Z.R., Russakov D.M., Lomzov A.A., Pyshnyi D.V., Gutakovsky A.K., Zhivodkov Y.A., Demidov E.A., Peltek S.E., Dolganyuk V.F., Babich O.O., Grigoriev E.V., Brusina E.B., Barbarash O.L., Yuzhalin A.E. Apoptosis-mediated endothelial toxicity but not direct calcification or functional changes in anticalcification proteins defines pathogenic effects of calcium phosphate bions. Sci Rep. 2016; 6: 27255. doi: 10.1038/srep27255.

3. Lind L., Skarfors E., Berglund L., Lithell H., Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol. 1997; 50 (8): 967-973. doi: 10.1016/S0895-4356(97)00104-2.

4. Foley R.N., Collins A.J., Ishani A., Kalra P.A. Calciumphosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008; 156 (3): 556-563. doi: 10.1016/j.ahj.2008.05.016.

5. Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., Strippoli G.F. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011; 305 (11): 1119-1127. doi: 10.1001/jama.2011.308.

6. Reid I.R., Gamble G.D., Bolland M.J. Circulating calcium concentrations, vascular disease and mortality: a systematic review. J Intern Med. 2016; 279 (6): 524-540. doi: 10.1111/joim.12464.

7. Yurdagul A. Jr., Finney A.C., Woolard M.D., Orr A.W. The arterial microenvironment: the where and why of atherosclerosis. Biochem J. 2016; 473 (10): 1281-1295. doi: 10.1042/BJ20150844.

8. Gimbrone M.A. Jr., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016; 118 (4): 620-636. doi: 10.1161/CIRCRESAHA.115.306301.

9. Jensen H.A., Mehta J.L. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Rev Cardiovasc Ther. 2016; 14 (9): 1021-1033. doi: 10.1080/14779072.2016.1207527.

10. Cahill P.A., Redmond E.M. Vascular endothelium - Gatekeeper of vessel health. Atherosclerosis. 2016; 248: 97- 109. doi: 10.1016/j.atherosclerosis.2016.03.007.

11. Young J.D., Martel J., Young D., Young A., Hung C.M., Young L, Chao Y.J., Young J., Wu C.Y. Characterization of granulations of calcium and apatite in serum as pleomorphic mineralo-protein complexes and as precursors of putative nanobacteria. PLoS One. 2009; 4 (5): e5421. doi: 10.1371/journal.pone.0005421.

12. Peng H.H., Wu C.Y., Young D., Martel J., Young A., Ojcius D.M., Lee Y.H., Young J.D. Physicochemical and biological properties of biomimetic mineralo-protein nanoparticles formed spontaneously in biological fluids. Small. 2013; 9 (13): 2297-2307. doi: 10.1002/smll.201202270.

13. Young J.D., Martel J., Young L., Wu C.Y., Young A., Young D. Putative nanobacteria represent physiological remnants and culture by-products of normal calcium homeostasis. PLoS One. 2009; 4 (2): e4417. doi: 10.1371/journal.pone.0004417.

14. Martel J., Young D., Young A., Wu C.Y., Chen C.D., Yu J.S., Young J.D. Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal Biochem. 2011; 418 (1): 111-125. doi: 10.1016/j.ab.2011.06.018.

15. Smith E.R., Hanssen E., McMahon L.P., Holt S.G. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One. 2013; 8 (4): e60904. doi: 10.1371/journal.pone.0060904.

16. Love S.A., Maurer-Jones M.A., Thompson J.W., Lin Y.S., Haynes C.L. Assessing nanoparticle toxicity. Annu Rev Anal Chem (Palo Alto Calif). 2012; 5: 181-205. doi: 10.1146/annurev-anchem-062011-143134.

17. Lai D.Y. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 4 (1): 1-15. doi: 10.1002/wnan.162.

18. Sukhanova A., Bozrova S., Sokolov P., Berestovoy M., Karaulov A., Nabiev I. Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties. Nanoscale Res Lett. 2018; 13 (1): 44. doi: 10.1186/s11671-018-2457-x.

19. Martel J., Wu C.Y., Hung C.Y., Wong T.Y., Cheng A.J., Cheng M.L., Shiao M.S., Young J.D. Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale. 2016; 8 (10): 5537-5545. doi: 10.1039/c5nr08116e.

20. Wu C.Y., Martel J., Young J.D. Comprehensive organic profiling of biological particles derived from blood. Sci Rep. 2018; 8 (1): 11310. doi: 10.1038/s41598-018-29573-6.

21. Barbarash L.S., Rogulina N.V., Rutkovskaya N.V., Ovcharenko E.A. Mechanisms underlying bioprosthetic heart valve dysfunctions. Complex Issues of Cardiovascular Diseases. 2018; 7 (2): 10-24. (In Russian)